FDA Raises Concerns Over Early Deaths in CAR-T Myeloma Trials
Washington, D.C. – The Food and Drug Administration (FDA) has raised concerns over early deaths observed in clinical trials for CAR-T cell therapies by Johnson & Johnson (J&J), Legend’s Carvykti, and Bristol Myers’ Abecma targeting patients with myeloma. These groundbreaking treatments are designed to utilize a patient’s own immune cells to fight cancer. CAR-T therapy … Read more